UPDATE 1-AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Apogee Therapeutics, Inc.
Nuvalent, Inc. Class A
AbbVie, Inc.
Regeneron Pharmaceuticals, Inc.
GlaxoSmithKline plc Sponsored ADR

Apogee Therapeutics, Inc.

APGE

0.00

Nuvalent, Inc. Class A

NUVL

0.00

AbbVie, Inc.

ABBV

0.00

Regeneron Pharmaceuticals, Inc.

REGN

0.00

GlaxoSmithKline plc Sponsored ADR

GSK

0.00

Adds shares details throughout.

June 22 (Reuters) - AbbVie ABBV.N said on Monday it would buy biotech Apogee Therapeutics APGE.O for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline.

AbbVie has offered $135.11 per Apogee share held, which implies a 49.49% premium to Thursday's close. Shares of Apogee were at $136.3 in premarket trading.

The deal gives AbbVie access to Apogee's lead drug candidate, zumilokibart, an experimental treatment targeting a range of inflammatory diseases, including moderate-to-severe atopic dermatitis and asthma.



This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.